De-ESCALaTE study shows cisplatin superior to cetuximab in treating HPV positive oropharyngeal cancer
16 November 2018
Results from our De-ESCALaTE HPV study were today reported in the Lancet. [see paper here - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32752-1/fulltext] The study funded by CRUK has shown that compared with the standard cisplatin treatment is superior to cetuximab.
Our thanks go to all our collaborators and especially to all the patients who took part. Without their participation into clinical trials this important question would not have been answered.
